Literature DB >> 1979335

A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia.

A C Moses1, H N Rosen, D E Moller, S Tsuzaki, J E Haddow, J Lawlor, J J Liepnieks, W C Nichols, M D Benson.   

Abstract

In a family expressing euthyroid hyperthyroxinemia, an increased association of plasma thyroxine (T4) with transthyretin (TTR) is transmitted by autosomal dominant inheritance and is secondary to a mutant TTR molecule with increased affinity for T4. Eight individuals spanning three generations exhibited the abnormality. Although five of eight individuals had elevated total T4 concentrations, all affected individuals were clinically euthyroid and all had normal free T4 levels. Purified TTR from the propositus had an affinity for 125I-T4 three times that of control TTR. Exons 2, 3, and 4 (representing greater than 97% of the coding sequence) of the TTR gene of DNA prepared from the propositus' peripheral blood leukocytes were amplified using the polymerase chain reaction (PCR) and were sequenced after subcloning. Exons 2 and 3 were indistinguishable from normal. In 50% of clones amplified from exon 4, a substitution of adenine (ACC) for guanine (GCC) in codon 109 resulted in the replacement of threonine-for-alanine, a mutation confirmed by amino acid sequencing of tryptic peptides derived from purified plasma TTR. The adenine-for-guanine substitution abolishes one of two Fnu 4H I restriction sites in exon 4. PCR amplification of exon 4 of TTR and restriction digestion with Fnu 4H I confirmed that five affected family members with increased binding of 125I-T4 to TTR are heterozygous for the threonine 109 substitution that increases the affinity of this abnormal TTR for T4.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979335      PMCID: PMC329840          DOI: 10.1172/JCI114938

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  The amino acid sequence of human plasma prealbumin.

Authors:  Y Kanda; D S Goodman; R E Canfield; F J Morgan
Journal:  J Biol Chem       Date:  1974-11-10       Impact factor: 5.157

2.  Familial euthyroid thyroxine excess: an appropriate response to abnormal thyroxine binding associated with albumin.

Authors:  J R Stockigt; D J Topliss; J W Barlow; E L White; D M Hurley; P Taft
Journal:  J Clin Endocrinol Metab       Date:  1981-08       Impact factor: 5.958

3.  A prealbumin variant with an increased affinity for T4 and reverse-T3.

Authors:  M R Lalloz; P G Byfield; R L Himsworth
Journal:  Clin Endocrinol (Oxf)       Date:  1984-10       Impact factor: 3.478

4.  Familial euthyroid hyperthyroxinemia resulting from increased thyroxine binding to thyroxine-binding prealbumin.

Authors:  A C Moses; J Lawlor; J Haddow; I M Jackson
Journal:  N Engl J Med       Date:  1982-04-22       Impact factor: 91.245

5.  Polymorphism of human plasma thyroxine binding prealbumin.

Authors:  F E Dwulet; M D Benson
Journal:  Biochem Biophys Res Commun       Date:  1983-07-29       Impact factor: 3.575

6.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

7.  Binding of reverse triiodothyronine to serum immunoglobulins in man and the rabbit.

Authors:  B N Premachandra; J Ginsberg; P G Walfish
Journal:  J Clin Endocrinol Metab       Date:  1980-04       Impact factor: 5.958

8.  Familial dysalbuminemic hyperthyroxinemia: a syndrome that can be confused with thyrotoxicosis.

Authors:  M Ruiz; R Rajatanavin; R A Young; C Taylor; R Brown; L E Braverman; S H Ingbar
Journal:  N Engl J Med       Date:  1982-03-18       Impact factor: 91.245

9.  Normal insulin-receptor cDNA sequence in Pima Indians with NIDDM.

Authors:  D E Moller; A Yokota; J S Flier
Journal:  Diabetes       Date:  1989-11       Impact factor: 9.461

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  9 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

2.  Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.

Authors:  Olgica Trenchevska; Elena Kamcheva; Dobrin Nedelkov
Journal:  Proteomics       Date:  2011-08-09       Impact factor: 3.984

3.  An association study between the transthyretin (TTR) gene and mental retardation.

Authors:  Jun Li; Jian-Jun Gao; Fu-Chang Zhang; Qing-He Xing; Fang-Li Dang; Xiao-Cai Gao; Shi-Wei Duan; Zi-Jian Zheng; Xue-Qing Qian; Wei Qin; Xing-Wang Li; Yan-Feng Han; Jing Li; Guo-Yin Feng; D St Clair; Lin He
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-12-19       Impact factor: 5.270

4.  Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations.

Authors:  A Gustavsson; U Engström; P Westermark
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

Review 5.  Inherited defects of thyroxine-binding proteins.

Authors:  Theodora Pappa; Alfonso Massimiliano Ferrara; Samuel Refetoff
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-09-30       Impact factor: 4.690

6.  A point mutation in the human serum albumin gene results in familial dysalbuminaemic hyperthyroxinaemia.

Authors:  C E Petersen; A G Scottolini; L R Cody; M Mandel; N Reimer; N V Bhagavan
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

7.  Transthyretin Ser 6 gene frequency in individuals without amyloidosis.

Authors:  D R Jacobson; I L Alves; M J Saraiva; S N Thibodeau; J N Buxbaum
Journal:  Hum Genet       Date:  1995-03       Impact factor: 4.132

8.  Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice.

Authors:  Laura Zemany; Sanjay Bhanot; Odile D Peroni; Susan F Murray; Pedro M Moraes-Vieira; Angela Castoldi; Prasad Manchem; Shuling Guo; Brett P Monia; Barbara B Kahn
Journal:  Diabetes       Date:  2014-12-18       Impact factor: 9.461

9.  Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.

Authors:  Ricardo Sant'Anna; Maria Rosário Almeida; Nathalia Varejāo; Pablo Gallego; Sebastian Esperante; Priscila Ferreira; Alda Pereira-Henriques; Fernando L Palhano; Mamede de Carvalho; Debora Foguel; David Reverter; Maria João Saraiva; Salvador Ventura
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.